{"id":"https://openalex.org/W2019495148","doi":"https://doi.org/10.1158/0008-5472.can-14-0138-t","title":"Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR2 Feedback Signaling","display_name":"Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR2 Feedback Signaling","publication_year":2014,"publication_date":"2014-04-18","ids":{"openalex":"https://openalex.org/W2019495148","doi":"https://doi.org/10.1158/0008-5472.can-14-0138-t","mag":"2019495148","pmid":"https://pubmed.ncbi.nlm.nih.gov/24747911"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.can-14-0138-t","doi":"https://doi.org/10.1158/0008-5472.can-14-0138-t","is_oa":false,"landing_page_url":"https://doi.org/10.1158/0008-5472.can-14-0138-t","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5015748000","display_name":"Marie Schoumacher","orcid":"https://orcid.org/0000-0001-5740-9825","observed_orcids":["https://orcid.org/0000-0001-5740-9825"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marie Schoumacher","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087335353","display_name":"Kristen E. Hurov","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristen E. Hurov","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090425458","display_name":"Joseph Leh\u00e1r","orcid":"https://orcid.org/0000-0001-7743-4366","observed_orcids":["https://orcid.org/0000-0001-7743-4366"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Leh\u00e1r","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020337361","display_name":"Yan Yan\u2010Neale","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yan Yan-Neale","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059882947","display_name":"Yuji M. Mishina","orcid":"https://orcid.org/0000-0002-6268-4204","observed_orcids":["https://orcid.org/0000-0002-6268-4204"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yuji Mishina","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006331883","display_name":"Dmitriy Sonkin","orcid":"https://orcid.org/0000-0002-1649-0652","observed_orcids":["https://orcid.org/0000-0002-1649-0652"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dmitriy Sonkin","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060683698","display_name":"Joshua M. Korn","orcid":"https://orcid.org/0000-0002-7751-0303","observed_orcids":["https://orcid.org/0000-0002-7751-0303"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joshua M. Korn","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031233222","display_name":"Daisy Flemming","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daisy Flemming","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063863419","display_name":"Michael D. Jones","orcid":"https://orcid.org/0000-0001-7541-7634","observed_orcids":["https://orcid.org/0000-0001-7541-7634"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael D. Jones","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019308752","display_name":"Brandon Antonakos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brandon Antonakos","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074912070","display_name":"Vesselina G. Cooke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vesselina G. Cooke","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046413668","display_name":"Janine L. Steiger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Janine Steiger","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071414787","display_name":"Jebediah Ledell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jebediah Ledell","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003511605","display_name":"Mark Stump","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark D. Stump","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057346782","display_name":"William R. Sellers","orcid":"https://orcid.org/0000-0002-3539-9803","observed_orcids":["https://orcid.org/0000-0002-3539-9803","https://orcid.org/0000-0003-2604-2498"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William R. Sellers","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065550933","display_name":"Nika N. Danial","orcid":"https://orcid.org/0000-0003-4842-1827","observed_orcids":["https://orcid.org/0000-0003-4842-1827"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nika N. Danial","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000020580","display_name":"Wenlin Shao","orcid":"https://orcid.org/0000-0003-2417-2221","observed_orcids":["https://orcid.org/0000-0003-2417-2221","https://orcid.org/0000-0003-0894-8210"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Wenlin Shao","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","Zalicus Inc., Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Department, Novartis Institutes for BioMedical Research; 2Zalicus Inc., Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Zalicus Inc., Cambridge","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5000020580"],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":null,"apc_paid":null,"fwci":1.2117,"has_fulltext":false,"cited_by_count":46,"citation_normalized_percentile":{"value":0.76700599,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"74","issue":"12","first_page":"3294","last_page":"3305"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9779999852180481,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9779999852180481,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.006399999838322401,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.0035000001080334187,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tankyrase","display_name":"tankyrase","score":0.972000002861023},{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":0.9929999709129333},{"id":"https://openalex.org/keywords/kras-mutation","display_name":"KRAS mutation","score":0.8550000190734863},{"id":"https://openalex.org/keywords/fgfr2-signaling","display_name":"FGFR2 signaling","score":0.9120000004768372},{"id":"https://openalex.org/keywords/feedback-signaling","display_name":"feedback signaling","score":0.621999979019165},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7080000042915344},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.8040000200271606},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.6399999856948853},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.777999997138977},{"id":"https://openalex.org/keywords/cancer-cell-lines","display_name":"cancer cell lines","score":0.6269999742507935}],"concepts":[{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.8489067554473877},{"id":"https://openalex.org/C137620995","wikidata":"https://www.wikidata.org/wiki/Q155769","display_name":"Wnt signaling pathway","level":3,"score":0.6871898174285889},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.5674952268600464},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5385199189186096},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4679248332977295},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.46608418226242065},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4459880590438843},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.42158135771751404},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.3913491368293762},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.366025447845459},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2932949662208557},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.1922532021999359},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08805859088897705},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.08804640173912048},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.08782973885536194}],"mesh":[{"descriptor_ui":"D000069347","descriptor_name":"Erlotinib Hydrochloride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000081","descriptor_name":"Acetamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000814","descriptor_name":"Aniline Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009025","descriptor_name":"Morpholines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011518","descriptor_name":"Proto-Oncogene Proteins","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D011744","descriptor_name":"Pyrimidinones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016283","descriptor_name":"Proto-Oncogene Proteins p21(ras)","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018631","descriptor_name":"ras Proteins","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D020930","descriptor_name":"MAP Kinase Kinase Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D020930","descriptor_name":"MAP Kinase Kinase Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D025461","descriptor_name":"Feedback, Physiological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D038501","descriptor_name":"Tankyrases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D038501","descriptor_name":"Tankyrases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051497","descriptor_name":"Receptor, Fibroblast Growth Factor, Type 2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D051497","descriptor_name":"Receptor, Fibroblast Growth Factor, Type 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1158/0008-5472.can-14-0138-t","doi":"https://doi.org/10.1158/0008-5472.can-14-0138-t","is_oa":false,"landing_page_url":"https://doi.org/10.1158/0008-5472.can-14-0138-t","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},{"id":"pmid:24747911","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24747911","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.6240000128746033,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":45,"referenced_works":["https://openalex.org/W1965006127","https://openalex.org/W1977181499","https://openalex.org/W1982313226","https://openalex.org/W1987508575","https://openalex.org/W1990484467","https://openalex.org/W1999460643","https://openalex.org/W2001999652","https://openalex.org/W2005909927","https://openalex.org/W2009333774","https://openalex.org/W2010022150","https://openalex.org/W2014784791","https://openalex.org/W2017822270","https://openalex.org/W2021087717","https://openalex.org/W2030733555","https://openalex.org/W2030777235","https://openalex.org/W2032578973","https://openalex.org/W2034373020","https://openalex.org/W2043398720","https://openalex.org/W2044025814","https://openalex.org/W2052177508","https://openalex.org/W2057257265","https://openalex.org/W2057706543","https://openalex.org/W2065585161","https://openalex.org/W2072528578","https://openalex.org/W2084875329","https://openalex.org/W2096175781","https://openalex.org/W2101096891","https://openalex.org/W2101889783","https://openalex.org/W2105240743","https://openalex.org/W2105437003","https://openalex.org/W2111927373","https://openalex.org/W2112140640","https://openalex.org/W2118474093","https://openalex.org/W2118666161","https://openalex.org/W2119780609","https://openalex.org/W2120492882","https://openalex.org/W2127403047","https://openalex.org/W2135131549","https://openalex.org/W2142194813","https://openalex.org/W2142859055","https://openalex.org/W2154533853","https://openalex.org/W2155228605","https://openalex.org/W2157016650","https://openalex.org/W2162871532","https://openalex.org/W6647125114"],"related_works":["https://openalex.org/W2056029681","https://openalex.org/W4252595377","https://openalex.org/W2346079527","https://openalex.org/W3182556473","https://openalex.org/W4245061930","https://openalex.org/W2944344791","https://openalex.org/W2470024294","https://openalex.org/W3019373524","https://openalex.org/W4237181213","https://openalex.org/W2091334045"],"abstract_inverted_index":{"Tankyrases":[0],"(TNKS)":[1],"play":[2],"roles":[3],"in":[4,21,41,53,84,87,114],"Wnt":[5],"signaling,":[6],"telomere":[7],"homeostasis,":[8],"and":[9,37,73,80,86,107],"mitosis,":[10],"offering":[11],"attractive":[12],"targets":[13],"for":[14],"anticancer":[15],"treatment.":[16],"Using":[17],"unbiased":[18],"combination":[19,104],"screening":[20],"a":[22,32,48,57,102,120],"large":[23],"panel":[24],"of":[25,51,56,71,105],"cancer":[26,43],"cell":[27],"lines,":[28],"we":[29],"have":[30],"identified":[31],"strong":[33],"synergy":[34],"between":[35],"TNKS":[36,52,72,106],"MEK":[38,62,74,108],"inhibitors":[39,109],"(MEKi)":[40],"KRAS-mutant":[42,116],"cells.":[44],"Our":[45],"study":[46],"uncovers":[47],"novel":[49,103],"function":[50],"the":[54],"relief":[55],"feedback":[58],"loop":[59],"induced":[60],"by":[61,92,118],"inhibition":[63,70],"on":[64],"FGFR2":[65],"signaling":[66],"pathway.":[67],"Moreover,":[68],"dual":[69],"leads":[75],"to":[76],"more":[77],"robust":[78],"apoptosis":[79],"antitumor":[81],"activity":[82],"both":[83],"vitro":[85],"vivo":[88],"than":[89],"effects":[90],"observed":[91],"previously":[93],"reported":[94],"MEKi":[95],"combinations.":[96],"Altogether,":[97],"our":[98],"results":[99],"show":[100],"how":[101],"can":[110],"be":[111],"highly":[112],"effective":[113],"targeting":[115],"cancers":[117],"suppressing":[119],"newly":[121],"discovered":[122],"resistance":[123],"mechanism.":[124]},"counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":9},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":3}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}